Sustainability & Responsibility (ESG)

Innovation Thrives on Trusted Exchange and Collaboration

All customers, cooperation partners and employees should feel welcome – regardless of educational background, age, gender identity, sexual orientation, physical and mental abilities, social background, nationality, religion or worldview.

DendroPharm is an equal opportunity employer. Our ESG status has been evaluated in conjunction with Creditreform.

We support the 17 Global Goals and are part of the support network for the Global Goals Berlin initiative. With our project "Pain therapy without the risk of addiction", we are committed to a future worth living. Our business activities focus in particular on the following four Global Goals:

Goal 3:

Ensure healthy lives and promote well-being for all at all ages. Through the development of non-addictive opiates and the general reduction of side effects, our research and development is closely linked to this sustainability goal.

Goal 9:

Build resilient infrastructure, promote inclusive and sustainable industrialization and foster innovation. Through cooperation with research institutions, we contribute to technology transfer. We also offer master's and bachelor's thesis positions for young scientists and, in cooperation with partners, doctoral positions. Our local production in Berlin helps to manufacture medicinal products regionally in order to be resilient in times of crisis.

Goal 12:

Responsible consumption and production: Our innovative nanocarrier production significantly reduces the use of raw materials – i.e. active ingredients. This contributes to saving resources. On site, we reduce our CO2 emissions through production that is as energy-efficient as possible.

Goal 17:

Partnerships for the goals: DendroPharm cooperates with partners from research and science. We are also open to partnerships with stakeholders from structurally weak regions. Specifically, since its foundation DendroPharm has been involved in 7 multi-year collaborative research projects (ZIM, Profit, BMBF) and works closely with research groups from veterinary and human medicine, chemistry and pharmaceutical technology as well as small and medium-sized enterprises. Partners include the Fraunhofer-Gesellschaft, Freie Universität Berlin, TU Berlin and BHT.